诺泰生物(688076) - 2024 Q2 - 季度业绩预告

Financial Performance Forecast - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 180 million and 250 million CNY, representing an increase of 138.15 million to 208.15 million CNY compared to the same period last year, a year-on-year increase of 330.08% to 497.34%[4] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for the first half of 2024 is also projected to be between 180 million and 250 million CNY, reflecting an increase of 136.99 million to 206.99 million CNY year-on-year, which corresponds to a growth of 318.59% to 481.38%[4] - In the same period last year, the total profit was 47.88 million CNY, with a net profit attributable to shareholders of 41.85 million CNY and a net profit after deducting non-recurring gains and losses of 43.00 million CNY[6] Performance Drivers - The significant growth in the company's performance is attributed to the continuous increase in the volume and revenue share of self-selected products[7] Audit and Risks - The performance forecast has not been audited by a registered accountant, indicating preliminary estimates[5] - There are risks associated with the recognition of revenue due to potential delays in shipping and logistics, which may affect some orders[9] - The forecast data is preliminary and the final financial data will be disclosed in the official 2024 semi-annual report[10]